Kessler Topaz Meltzer & Check, LLP - Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; March 13, 2026, Lead Plaintiff Deadline

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for misleading statements regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [2][4][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][6][8]. - The allegations include that Ultragenyx misrepresented the reliability of data regarding setrusumab's effects on Osteogenesis Imperfecta and downplayed risks associated with its Phase III Orbit study [4][7]. Group 2: Stock Performance - On December 29, 2025, Ultragenyx's stock price dropped over 42%, from $34.19 per share on December 26, 2025, to $19.72 per share, following the announcement that its Phase III studies did not achieve statistical significance [5]. Group 3: Investor Actions - Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [3][9]. - Investors can choose to file for lead plaintiff status or remain as absent class members, with the lead plaintiff representing the interests of the class [8].